DEF: Mirum Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting

Mirum Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders on May 29, 2025, to elect directors, ratify the selection of Ernst & Young LLP as the independent registered public accounting firm, and conduct an advisory vote on executive compensation.

Summary

• Mirum Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders on May 29, 2025, at 9:00 a.m. Pacific Time at the company's headquarters in Foster City, California.
• Stockholders of record as of April 3, 2025, are eligible to vote.
• The meeting will address the election of three Class III director nominees for terms expiring in 2028, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
• Stockholders can vote in person, by telephone, via the internet, or by mail.
• The proxy statement and annual report are available at www.proxyvote.com.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions, but does not express strong positive or negative sentiment.

Positives

• The company is providing multiple methods for stockholders to vote, including in person, by telephone, via the internet, or by mail.
• The company is making the proxy statement and annual report available online at www.proxyvote.com, promoting accessibility for stockholders.

Future Outlook

The document outlines the agenda and procedures for the upcoming annual meeting, focusing on governance matters and providing stockholders with the opportunity to influence key decisions.

Management Comments

• Christopher Peetz, Chief Executive Officer, cordially invited stockholders to attend the 2025 Annual Meeting.

Industry Context

This is a standard proxy statement outlining routine corporate governance matters for a publicly traded pharmaceutical company.

Comparison to Industry Standards

• The proxy statement's content and format align with standard practices for publicly traded companies, similar to those of Acadia Pharmaceuticals, BioMarin Pharmaceutical Inc., and Horizon Therapeutics plc.
• The proposals to elect directors, ratify the auditor, and conduct an advisory vote on executive compensation are typical agenda items for annual meetings of publicly traded companies.

Stakeholder Impact

• Stockholders have the opportunity to vote on key governance matters, influencing the direction of the company.
• The outcome of the votes will impact the composition of the Board of Directors and the selection of the independent auditor.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on May 29, 2025, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Ernst & Young, Voting, Mirum Pharmaceuticals